<DOC>
	<DOCNO>NCT00004443</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess safety efficacy NTBC child tyrosinemia I. II . Evaluate effect NTBC survival , rate neurologic crisis , improvement renal tubular damage , reduction need liver transplantation , reduction development hepatocarcinoma patient .</brief_summary>
	<brief_title>Study NTBC Tyrosinemia I</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients stratify accord age onset symptom ( 0-2 month v 2-6 month v great 6 month ) . Patients receive oral NTBC twice day . Treatment continue absence unacceptable toxicity . Patients follow month 6 month , every 3 month thereafter . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Tyrosinemias</mesh_term>
	<criteria>Confirmed diagnosis tyrosinemia Detected newborn screen onset symptom OR Diagnosed basis symptom ( liver disease , neurological crisis , growth failure ) succinylacetone urine blood and/or fumarylacetoacetate dehydratase deficiency culture fibroblast liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>tyrosinemia I</keyword>
</DOC>